Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
53 hedge funds and large institutions have $189M invested in Oyster Point Pharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 23 closing their positions.
68% more capital invested
Capital invested by funds: $113M → $189M (+$76.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
11.5% less ownership
Funds ownership: 74.67% → 63.18% (-11%)
12% less funds holding
Funds holding: 60 → 53 (-7)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
42% less call options, than puts
Call options by funds: $631K | Put options by funds: $1.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$6.35M |
| 2 |
GF
Gabelli Funds
Rye,
New York
|
+$6.31M |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$5M |
| 4 |
Man Group
London,
United Kingdom
|
+$3.1M |
| 5 |
RI
RTW Investments
New York
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.1M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$9.26M |
| 3 |
BlackRock
New York
|
-$4.87M |
| 4 |
TAM
Telemark Asset Management
Boston,
Massachusetts
|
-$4.37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.01M |
OYST Hedge Fund Activity: Q4 2022 in Review
53 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q4 2022, worth a combined $189M — up 68% from $113M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of OYST and 18 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was Westchester Capital Management (New York), opening a new position worth an estimated $6.35M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $10.1M sold.
- 53 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q4 2022, down from 60 in Q3 2022.
- Funds reported $189M of Oyster Point Pharma, Inc. Common Stock stock for Q4 2022, up 68% quarter-over-quarter.
- 18 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q4 2022 and 23 closed out, a net change of -5 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q4 2022 was Westchester Capital Management (New York), an estimated $6.35M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q4 2022 was Point72 Asset Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q4 2022.